share_log

Artelo Biosciences Presents Phase 1 Data On ART27.13 For Cancer-Related Anorexia At International Conference, Highlighting Good Tolerability And Weight Stabilization Or Reversal In Two-Thirds Of Participants; Phase 2 Enrollment Ongoing In CAReS Trial

Artelo Biosciences Presents Phase 1 Data On ART27.13 For Cancer-Related Anorexia At International Conference, Highlighting Good Tolerability And Weight Stabilization Or Reversal In Two-Thirds Of Participants; Phase 2 Enrollment Ongoing In CAReS Trial

artelo biosciences 在國際會議上展示了 ART27.13 針對癌症相關厭食症的第一階段數據,強調在三分之二的參與者中良好的耐受性以及體重的穩定或逆轉;CAReS 試驗的第二階段入組正在進行中
Benzinga ·  12/09 22:16

Artelo Biosciences Presents Phase 1 Data On ART27.13 For Cancer-Related Anorexia At International Conference, Highlighting Good Tolerability And Weight Stabilization Or Reversal In Two-Thirds Of Participants; Phase 2 Enrollment Ongoing In CAReS Trial

artelo biosciences 在國際會議上展示了 ART27.13 針對癌症相關厭食症的第一階段數據,強調在三分之二的參與者中良好的耐受性以及體重的穩定或逆轉;CAReS 試驗的第二階段入組正在進行中

声明:本內容僅用作提供資訊及教育之目的,不構成對任何特定投資或投資策略的推薦或認可。 更多信息
    搶先評論